logged the libido drop at month 3 on 10mg tirz in a post a few days ago, but i left out one detail: dryness showed up in the same window. not severe enough to cause pain, but present enough that i noticed and started tracking. i’m 39. no perimenopausal markers I can find. FSH in normal range, cycles regular, no hot flashes. so the obvious explanation doesn’t fit cleanly. the confound i keep coming back to: post-sleeve patients have less adipose tissue than people with intact anatomy at similar weights. adipose is a major site of peripheral aromatization, where androgens convert to estrogen locally. the sleeve didn’t fix my estrogen production, but it reduced one of the main tissue pools contributing to it. add tirzepatide driving further fat reduction, and i’m genuinely uncertain whether the combined effect on peripheral estrogen is enough to feel it locally, especially in tissue that’s sensitive to local levels. this is observation, not study-backed. I haven’t found dose-response data on tirz and vaginal dryness in post-bariatric patients specifically, because we’re excluded from most of the relevant trials. the other possibility is the hypothalamic one. GLP-1 receptors are distributed in the hypothalamus, which runs appetite and reproductive function through overlapping circuitry. food noise quieted in the same month as libido and the dryness. that’s either a shared mechanism or coincidental timing, and i haven’t ruled out either. my surgeon knows i’m tracking this. her read: wait for two or three cycles of stable data before drawing conclusions. i think that’s right. i’m not reaching for vaginal estrogen yet bc i don’t have a confirmed estrogen-deficient picture. but i’m closer to asking for the labs that would point toward or away from it than i was six weeks ago.
one piece nobody’s surfaced yet: if you do go for the labs, the assay matters more than people realize. standard immunoassay e2 is notoriously unreliable in the low female range, the cv gets ugly below ~30 pg/mL which is exactly where a peripheral aromatization signal would live. LC-MS/MS (sometimes labeled “sensitive estradiol”) is the one to specifically ask for, and most outpatient labs won’t run it by default unless you name it. while you’re at it, SHBG is worth tacking on, GLP-1s tend to nudge SHBG up as weight comes off, and free fractions of T and E2 are what local tissue actually sees, so a normal-looking total can hide a meaningful free shift. ymmv on whether your gyn or surgeon will order both.
The assay specificity case is solid, and the LC-MS/MS point is the piece I wasn’t fully accounting for when I wrote the OP. If the signal I’m chasing lives below 30 pg/mL, immunoassay noise swamps it before I can interpret anything meaningful, so that’s a real practical gap. The SHBG framing is where I’d push back. “GLP-1s tend to nudge SHBG up” conflates two things: weight loss raises SHBG (well-established), and tirz causes weight loss. The GLP-1-specific SHBG effect, independent of fat mass reduction, is murkier than that framing implies. If I’m trying to understand whether free fraction shifts explain what I’m seeing, SHBG is still worth running, but attributing any change to the drug rather than the fat loss requires controlled data the standard panel won’t provide. The free fraction point is mostly right but slightly incomplete for the specific symptom I flagged. Vaginal tissue does intracrine estrogen synthesis locally from androgen precursors, so circulating free E2 doesn’t fully capture what that tissue is actually seeing. That makes the peripheral aromatization argument in my OP more relevant, not less, but it also means even a clean sensitive estradiol panel might understate the local picture. Which is frustrating bc it suggests the labs narrow the differential without closing it.
the intracrine point is the one i’d sit with longest here. once you’re saying the tissue is doing its own local synthesis from precursors, the substrate pool matters as much as the aromatization step, and post-sleeve DHEA-S can run on the lower end without it being flagged on a standard panel because the reference range is wide and you’re not symptomatic for adrenal stuff. so the confound your OP stacked (less adipose, less peripheral aromatization) has a second floor under it: less substrate feeding into the local intracrine pathway in the first place. that doesn’t change your read that the labs narrow without closing, it just means the panel that gets you closer is probably sensitive E2 + free T + SHBG + DHEA-S, not just the first three. on the SHBG concession, agree the GLP-1-specific effect independent of fat loss is genuinely murky in the literature and i’d been letting that framing slide more than i should. fwiw the kind of multi-marker tracking this is going to need across two-three cycles is exactly the case where i stopped trying to make a spreadsheet work, the dark-mode chart colors are the small thing that got me actually logging at night instead of pretending i’d remember in the morning.
The bit that stayed with me reading this is “FSH in normal range, cycles regular.” Both of those are true facts about your bloods, but I’d be careful about letting a single FSH draw close down the perimenopause question at 39, because FSH bounces hard across cycle phase and even harder across the perimenopause window itself. One reading on one day is a snapshot, not a ruling out. A consultant friend explained it to me as “you can have a perfectly normal FSH on a Tuesday and a flagged one on the Friday of the same cycle,” and that’s before you layer in the year-to-year drift. Not saying it IS peri, just that “labs were normal” is getting used to close down a hypothesis a single panel can’t actually close at your age. The peripheral aromatization piece you’re describing is the part I haven’t seen anyone in these threads name as cleanly as you have, and the sleeve plus tirz sequence is doing real work in it. The thing I’d add, gently, is that you’re effectively comparing a current state to a baseline that’s already shifted twice (pre-sleeve, post-sleeve, post-tirz), and any ratio you draw between symptom onset and a current lab will be sitting on top of that. So if you do ask your GP for labs, I’d ask about estradiol and free testosterone together rather than estradiol alone, because the aromatization story is really about the ratio rather than the absolute number, and a single estradiol read in isolation has the same single-panel problem as the FSH did. Your surgeon’s “two or three cycles of stable data” is the right instinct in spirit, but my own experience has been that the resolution window for hormonal-feeling shifts varies a lot more across starting BMIs than the standard advice admits. Two friends sat with similar patterns for closer to four and five cycles before things either stabilised or declared themselves. So I’d hold that two-to-three window loosely rather than tightly, and not panic if it takes a bit longer to tell the story. Wishing you a clean read either way.
The adipose aromatization piece is the one I’d push back on least - that’s a real downstream consequence of sleeve plus continued fat reduction that doesn’t come up in these conversations nearly as much as it should. The caveat is about what the labs you’re moving toward can actually sort. Estradiol at cycle day 3 could be normal-range while the hypothalamic piece is still running in parallel, and a reassuring panel might close a question that’s still open. What would actually differentiate the two hypotheses is harder to order: SHBG trend, free testosterone across a couple cycles, maybe DHEAS. The hypothalamic quieting route doesn’t register reliably on a standard estrogen workup, especially in someone whose cycles are regular and FSH is in range, which fits the profile you’re describing. A “confirmed estrogen-deficient picture” is a high bar to clear when one of your candidate mechanisms bypasses the markers you’d use to confirm it. Waiting for stable data before drawing conclusions is right. Just worth defining what data would actually answer which question before you get the results, so a normal estrogen picture doesn’t end the inquiry when the hypothalamic angle is still unaddressed.